Week of July 19th 2021 | Vol. 10, Issue 29
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Eli Lilly and Company is set to acquire the remaining shares of biotech firm Protomer Technologies in a deal valued more than $1bn.

The latest move follows Lilly’s equity investment in Protomer along with the JDRF T1D Fund, acquiring the biotech company’s 14% stake.

Under the terms of the deal, Lilly will acquire the remaining shares of Protomer along with the development and commercial milestones in the future.

Protomer produces next-generation protein therapies which can sense molecular activators in the body and activate automatically based on the requirement.

The company’s peptide- and protein-engineering platform can be used to identify and synthesise molecules which can sense glucose or other endogenous modulators of protein activity.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
8 transactions totaling $681 million
Supplies, Equipment & Services
22 transactions totaling $75 million
Healthcare IT & Managed Care
4 transactions totaling $16 million
Healthcare Facilities & Distributors
4 transactions
Pharma & Biotech
26 transactions totaling $1,023 million
Supplies, Equipment & Services
17 transactions totaling $382 million
Healthcare IT & Managed Care
9 transactions totaling $183 million
Healthcare Facilities & Distributors
1 transaction
Pharma & Biotech
12 transactions totaling $2,054 million
Supplies, Equipment & Services
2 transactions totaling $78 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
July 16, 2021 - Fierce Pharma
Chinese vaccine producers Sinovac and Sinopharm will supply up to 500 million doses of the COVID-19 vaccine to the COVAX worldwide relief effort. Japan-based Astellas and partner Seagen scored two FDA approvals on one day for their bladder cancer treatment Padcev. According to Reuters, BGI Group and the Chinese military have shared data on millions of pregnant women who have used BGI's genetic test.

July 16, 2021 - Fierce Pharma
Pfizer and two of its subsidiaries, Meridian Medical Technologies and King Pharmaceuticals, have agreed to fork over $345 million to settle years of antitrust litigation surrounding the pricey anaphylaxis injectable EpiPen. Mylan, now known as Viatris, sold the medicine, while Pfizer's subsidiaries helped with production.

July 14, 2021 - Fierce Pharma
Turns out, it was all but a false alarm for AstraZeneca. Despite threats of antitrust actions, the British drugmaker is now set to wrap up its $39 billion acquisition of Alexion Pharma next week. Wednesday, AstraZeneca said the U.K.’s Competition and Markets Authority (CMA) has cleared the Alexion buyout without raising any antitrust concerns. The g-ahead follows blessings from anticompetition authorities in the U.S. and EU and marks the final regulatory approval the company needs to seal the deal, which is now expected to close July 21.

July 14, 2021 - Contract Pharma
Ashfield, part of UDG Healthcare, has launched EmerGENE, a global end-to-end cell and gene therapy network approach designed to support small and midsize biotechs with the commercialization of their discoveries.
Events Hosted or Attended by Bourne Partners

August 10-12,2021 - Pennsylvania, PA

November 9-11,2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.